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OBJECTIVES: To aid interpretation of scores on the Living with
COPD scale (LCOPD; scored 0–22), COPD and Asthma Sleep
Impact Scale (CASIS; scored 0–100) and COPD and Asthma
Fatigue Scale (CAFS, scored 0–100). These new patient reported
outcome measures, designed for use in clinical trials, have previ-
ously been shown to be reliable and valid.METHODS:Question-
naire data from UK (n = 162; 46% male; mean age = 69.3 years)
and US (n = 145; 51% male; mean age = 71.7 years) surveys were
analysed. Mean questionnaire scores were evaluated against cli-
nician severity rating and by exacerbation status (US only). Effect
sizes (ES) and standard errors of measurement (SEM)were used to
provide a preliminary estimate of the minimal important dif-
ference (MID). RESULTS: Scores on the LCOPD and CAFS
were signiﬁcantly related to clinician rating of COPD severity
(p < 0.001). A similar trend for the CASIS was not statistically
signiﬁcant. Scores on all measures were also signiﬁcantly higher
(p < 0.05), indicating greater impairment if the patient had had an
exacerbation in the previous week. For the LCOPD the values for
0.3 ES, 0.5 ES and SEMwere 2.0, 3.3 and 1.4 respectively. For the
CASIS the ﬁgures were 7.4, 12.3 and 7.4 and for the CAFS; 7.3,
12.2 and 5.5. Therefore, these distribution-based analyses suggest
that the MID is in the region of 2 for the LCOPD and 7 for the
CASIS and CAFS. CONCLUSIONS: The analyses provide pre-
liminary information on how to interpret scores on the scales.
Further analyses of longitudinal data are required to conﬁrm these
ﬁndings, to assess anchor-based estimates and to allow greater
precision in powering studies using these questionnaires.
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OBJECTIVES: Fatigue experienced by cancer patients need to be
assessed carefully. Yet, there is no agreement on the most appro-
priate recall period to use. In this study, we compared responses
to identical fatigue item pairs, varying only the reporting period
(past 7-days versus past 4-weeks), and explored factors that
inﬂuenced patients’ responses. METHODS: Sample included 216
cancer patients (63.5% female, 80.5% white, mean age = 57.6;
36% had breast cancer). Patients were asked to complete either
a 7-day (n = 100) or 4-week (n = 116) version of the Func-
tional Assessment of Chronic Illness Therapy-Fatigue. Cochran-
Mantel-Haenszel statistics (CMH) and Cochran-Armitage trend
tests were used to assess the association between time frame
and item scores. Information function curves at both item and
scale levels were depicted to evaluate the precision along the
fatigue continuum. Differential item functioning (DIF) was used
to examine the psychometric stability between time frames.
RESULTS: These two sample groups had comparable degree of
fatigue severity at the time of survey (p = 0.209) and at the end of
survey (p = 0.074), as measured with a single 0–10 rating. No
item was rejected by CMH or trend tests at p < 0.01, indicating
that time frame did not inﬂuence patients’ responses. Similarly,
item information curves did not clearly favor either time frame.
No item demonstrated DIF between time frames. Results of
chi-square statistics showed that both gender and fatigue severity
were not signiﬁcantly associated with the time frame patients
reported using to endorse items, p = 0.48 and p = 0.33, respec-
tively. CONCLUSIONS: This study suggests the 7-day and
4-week time frame are equally appropriate in measuring fatigue.
Slight preference might be given to the more informative 7-day
reporting period. However, substantive considerations regarding
the appropriate time frame should outweigh statistical ones.
Comparison of the 7-day time frame to shorter ones (e.g., 24
hour) is needed.
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Organization: Ministry of Health in Poland (MoH), Agency for
Health Technology Assessment in Poland (AHTAPol).
Problem or Issue Addressed: The European Commission (EC)
has pointed out certain areas for improvement in the process of
reimbursement decision—making in Poland, especially in the
ﬁeld of transparency and compatibility with Directive 89/105/
EEC and EC jurisprudence as well as long delays in making
decisions. Moreover the pharmaceutical industry complained
about too long and unclear decision making process. It should
have been improved in areas such as: setting deadlines for taking
decisions; objective and veriﬁable criteria; clear and adequate
information of the decision to applicants; inclusion of expert
opinions in the process of conducting decisions.
Goals: To establish decision—making system, transparent and
clear for all stakeholders and in line with the Transparency
Directive.
Outcomes items used in the decision: In the decisions – making
process on drug reimbursement Poland uses outcomes concern-
ing effectiveness and safety, cost-effectiveness, budget impact
analyses, health priorities and price negotiations.
Implementation Strategy: To solve the above—mentioned prob-
lems an EU Twinning Project between Poland and France was
signed and took place between October 2006 and April 2008.
The European experts analyzed the Polish reimbursement system
and gave recommendations on how to improve it. During the
Project employees of MoH and AHTAPol were sent on study
trips and internships to gain knowledge about other Europeans
systems and work in different institutions involved.
Moreover the several workshops and conferences took place
during and after the EU Project with all involved stakeholders to
set up the best available drug reimbursement decision making
process. During the workshops we used recommendations done
by EU experts as well as other countries experiences. The work-
shops were divided into 3 groups based on their tasks: to identify
reimbursement and pricing criteria; to divide responsibilities
between main actors and to deﬁne role of different stakeholders
involved in the process. The ﬁrst seminar aimed at creating the
momentum in which the necessary political decisions could be
made. During this seminar three Vice-Ministers of the Ministry
of Health conﬁrmed that a new comprehensive Bill on reimburse-
ment decisions would encompass the entire procedure of
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decision-making, from the moment of ﬁrst application until the
ﬁnal decision made by the Ministry.
Results: As a result of the workshops the detailed process of
making reimbursement decisions has been speciﬁed and the cri-
teria for reimbursement and pricing are being deﬁned. Bill regu-
lating the reimbursement system in Poland is being prepared and
will be implemented into polish legal system in January 2009.
The Bill regulates the tasks of HTA Agency, its Consultative
Council, which makes recommendations, and MoH in the
process. It names the health priorities taken into account while
giving recommendations, lists all the documents and analyses
required in the reimbursement application.
A separate Regulation will be prepared with the template of
the reimbursement application and description of properly write
analyses based on polish HTA guideline.
The process of including (or excluding) drug to the reimburse-
ment list is divided on the steps taking place in different institu-
tions. The separate tracks are set for innovative drugs and for
generics. The specialized institutions are responsible for each
step: clinical effectiveness, safety and cost effectiveness is assessed
in AHTAPol, formal and legal requirements in MoH, price nego-
tiations by special Negotiations Committee and ﬁnal recommen-
dations to Minister is made by Reimbursement Committee which
advice the Minister of Health.
The documents prepared in each step of the process will be
transparent and available for all stakeholders except price nego-
tiations which are conﬁdential and results are known only to the
Ministry and the company involved.
The whole process described above will result in a clear and
transparent system of drug reimbursement in Poland, which will
be implemented into the Polish legal system in 2009. That was
big and important project, which improved cooperation between
policy makers and industry, between international HTA experts
and between Poland, France, the EC and other Member States.
Lessons Learned: For creating a new or improving existing reim-
bursement decision making process experience of other countries
is indispensible. Changes in the process should be transparent,
understandable for all stakeholders and if possible consulted
with all parties involved; policy makers, EC, industry, health
professionals and patients associations.
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Problem or Issue Addressed: There have been numerous concerns
and criticisms that results from Health Technology Assessment
(HTA) reports or economic evaluations are infrequently used in
health care decision making and subsequent policy formation. It
is apparent that favorable and good quality clinical and eco-
nomic evidence is not a sufﬁcient condition for policy develop-
ment. It has been hypothesized that Conditionally Funded
Field Evaluations (CFFEs)/Conditional funding with Evidence
Development (CED) may provide decision makers with the
information needed to better inform policy recommendations
and development.
Goals: To compare, in a large health care system, policy devel-
opment and uptake for technologies based on information
collected from local/geographic-speciﬁc clinical and cost-
effectiveness studies showing how a technology works in a ‘real
world’ setting to policy uptake for technologies based on tradi-
tional HTA evidence collection and synthesis techniques.
Outcomes items used in the decision: The Ontario Ministry of
Health and Long Term Care (MOHLTC) has embarked on a
relatively new initiative for publicly ﬁnanced health care deci-
sion making for new devices and medical technologies that is
embedded in an evidence-based framework. All requests for
new public funding are funneled through an independent multi-
disciplinary decision making body (Ontario Health Technology
Advisory Committee). OHTAC may either request that the
MOHLTC conduct an internal review of the available evidence
surrounding the technology (i.e. traditional literature review
and syntheses techniques) or that a CFEE/CED be conducted
due to insufﬁcient information and high decision uncertainty.
This uncertainty can arise from conﬂicting, poor quality, or
insufﬁcient evidence or simply due to concerns about general-
izability of the technology to the Ontario setting. Based on
whether the technology followed the traditional approach for
evidence generation or the CFEE/CED approach, the rates of
subsequent policy development and uptake over the last 5 years
have been compared.
Implementation Strategy: Since its inception in 2003 OHTAC has
reviewed and made policy recommendations for over 100 tech-
nologies. Of the technologies that have resulted in recommenda-
tions for funding, 5 of these were based on completed CFFE/
CED.
Results: The policy uptake rate for technologies based on favor-
able reviews from the traditional review and synthesis approach
has been low (less than 20%) while the policy uptake rate for
technologies based on CFFE/CED has been 100%.
Lessons Learned: Reducing decision uncertainty through CFFE/
CED appears to provide policy makers with the stronger eviden-
tiary base needed for reimbursement and policy decision making.
Decision makers in other jurisdictions can learn from the expe-
riences to date from the OHTAC. We have started to help initiate
CFFE/CED programs in other provinces. Bottom of Form.
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Committee.
Problem or Issue Addressed: Feasibility of value-based pricing for
pharmaceuticals in Iceland.
Goals: To explore the feasibility of implementing value-based
pricing of patented pharmaceuticals in Iceland, and in case of it
being feasible, to ﬁnd a suitable model.
Outcomes items used in the decision: Literature searched for
value-based pricing models in developed countries, a model
chosen for further exploration and facilitators and hindrances in
the chosen model mapped before implementation. The chosen
model was the Swedish one, based on a few facts:
• Sweden is geographically quite close to Iceland.
• The culture of the two nations and health care system is in
many ways quite similar.
• There seems to be a general agreement on the Swedish
approach being the most rational of the value-based pricing
approaches in use currently in Europe.
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